UBS calls Auxilium a 'sleeper pick' for 2014 UBS believes investors are overlooking Auxilium's highly leveraged business model which will be driven by strong Xiaflex, Stendra, and Testopel growth, and stabilizing Testim. The firm expects operating margins to move towards 30% by 2016-17 from approximately 10% in 2013 and a pathway for 30% stock return performance over the next year. Shares are Buy rated with a $30 price target, up from $23.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.